Financial Performance - Revenue for Q3 2023 reached $5 million, a 19% increase compared to $4.2 million in Q3 2022[15] - Revenue for the nine months ended September 30, 2023, totaled $13.4 million, also a 19% increase compared to $11.2 million for the same period in 2022[15] - UltraMist consumables revenue increased by 24% to $3.1 million, constituting 62% of overall revenues in Q3 2023[15] - Net loss for the three months ended September 30, 2023, was $23.7 million, compared to a net loss of $1.1 million for the same period in 2022, primarily due to non-cash losses on the fair value of derivative liabilities[15] - Adjusted EBITDA loss for Q3 2023 was $0.3 million, an improvement of $1.9 million compared to a loss of $2.2 million in Q3 2022[15] Operational Highlights - 55 UltraMist systems were sold in Q3 2023, an increase from 28 in Q1 2023 and 49 in Q2 2023[15] - Gross margin was 71% for the three months ended September 30, 2023, slightly down from 72% in the same period last year[15] Future Outlook - The company anticipates Q4 2023 revenue will increase approximately 15% to 25% as compared to Q4 2022[17] Corporate Developments - In July 2023, the company issued Asset-Backed Secured Promissory Notes, receiving total proceeds of approximately $3 million[19] - SANUWAVE Health entered into a merger agreement with Sweat Equity Partners and Mercury Life Sciences-affiliated SEP Acquisition Corp in August 2023, with the combined company expected to trade on Nasdaq under the symbol "SNWV"[19]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 13, 2024 SANUWAVE Health, Inc. | (Exact name of registrant as specified in its charter) | | | | --- | --- | --- | | Nevada | 000-52985 | 20-1176000 | | (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) | | 11495 Valley View Road ...

Financial Performance - Q1 2025 revenues reached $9.3 million, marking a 61% increase from $5.8 million in Q1 2024, representing the highest quarterly revenues in the company's history [1][5] - Gross margin for Q1 2025 was 79.0%, up from 72.6% in Q1 2024 [1][5] - GAAP Operating Income for Q1 2025 was $1.0 million, an increase of $2.0 million compared to Q1 2024 [1][5] - The company reported a net loss of $5.7 million in Q1 2025, compared to a net loss of $4.5 million in Q1 2024 [5][21] Sales and Market Activity - The company sold 98 UltraMist® systems in Q1 2025, which is 128% more than the 43 systems sold in the same quarter last year [3][5] - UltraMist® consumables revenue increased by 43% to $5.8 million in Q1 2025, accounting for 99% of the company's overall revenues [5][21] Future Guidance - The company provides guidance for Q2 2025 revenue growth of 40-50% compared to Q2 2024, estimating revenues between $10.0 million and $10.7 million [4][5] - Full year 2025 revenue guidance is reiterated at $48-50 million, indicating a 47-53% increase compared to full year 2024 revenue [4][5] Operational Strategy - The company is focused on expanding its commercial operations and clinical teams to support ongoing growth while enhancing profitability [3] - The company has achieved comfortable inventory levels for both systems and applicators, allowing for aggressive engagement with larger customers [3]